SNCA and Parkinson disease: In the central nervous system (CNS), AAV vectors are being explored for delivery of Abs targeting neurodegenerative disease biomarkers, such as amyloid beta in Alzheimer’s disease and alpha-synuclein in Parkinson’s disease (112, 120–124).